



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/881,041

06/15/2001

Glenn Philander Vonk

39994

5157

26253 7590 07/28/2009
David W. Highet, VP & Chief IP Counsel
Becton, Dickinson and Company
1 Becton Drive
MC 110
Franklin Lakes, NJ 07417-1880

EXAMINER

SEREBOFF, NEAL

ART UNIT

PAPER NUMBER

3626

MAIL DATE

DELIVERY MODE

07/28/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

1 UNITED STATES PATENT AND TRADEMARK OFFICE

2
3
4 BEFORE THE BOARD OF PATENT APPEALS
5 AND INTERFERENCES
6

7
8 *Ex parte* GLENN PHILANDER VONK, ANN K. FRANTZ,
9 DAVID JOSHUA WHELLAN, CHRISTOPHER MICHAEL O'CONNOR,
10 and GEORGE B. GOLDMAN
11

12
13 Appeal 2009-003953
14 Application 09/881,041
15 Technology Center 3600
16

17
18 Decided:¹ July 28, 2009
19
20

21
22 Before HUBERT C. LORIN, ANTON W. FETTING, and JOSEPH A.
23 FISCHETTI, *Administrative Patent Judges*.

24
25 FETTING, *Administrative Patent Judge*.
26

27
28 DECISION ON APPEAL

¹ The two month time period for filing an appeal or commencing a civil action, as recited in 37 C.F.R. § 1.304, begins to run from the decided date shown on this page of the decision. The time period does not run from the Mail Date (paper delivery) or Notification Date (electronic delivery).

STATEMENT OF THE CASE

Glenn Philander Vonk, Ann K. Frantz, David Joshua Whellan, Christopher Michael O'Connor, and George B. Goldman (Appellants) seek review under 35 U.S.C. § 134 (2002) of a final rejection of claims 1-25, the only claims pending in the application on appeal.

We have jurisdiction over the appeal pursuant to 35 U.S.C. § 6(b) (2002).

We AFFIRM and ENTER A NEW GROUND OF REJECTION PURSUANT TO 37 C.F.R. § 41.50(b).

The Appellants invented a system and method for healthcare managers and healthcare providers to interactively cooperate with patients to monitor and evaluate patient status to provide the most appropriate treatment for the patients in the most cost-effective manner (Specification ¶ 0003).

An understanding of the invention can be derived from a reading of exemplary claims 1, 8, 15, 21, and 22, which are reproduced below [bracketed matter and some paragraphing added].

1. A system for monitoring health-related conditions of patients, comprising:

[1] a plurality of remote monitoring stations, each being configured to receive patient health-related data pertaining to a respective patient; and

[2] a computer network comprising a database containing accumulated health-related data pertaining to health-related conditions and treatments that reveals population trends and outcomes and at least one data access device configured to provide a health care provider access to said computer network and said database, said computer network configured to receive said patient health-related data pertaining to respective patients from said remote monitoring stations and provide a health care provider with electronic treatment establishment tools to establish treatment programs for said patients based on their

1 respective patient health-related data and said accumulated
2 health-related data, and said computer network configured to
3 revise said accumulated health-related data based on said
4 patient health-related data for identification of improvements in
5 standards of care and medical practices that can be made for
6 different ones of the health-related conditions;

7 [3] said remote monitoring stations being configured with
8 electronic self-management tools for receiving from a
9 respective patient said patient health-related data relating to
10 integration of a selected one of said treatment programs into the
11 patient's lifestyle comprising at least one of questions
12 concerning health or treatment and responses to questions
13 concerning health or treatment that are generated using said
14 electronic self-management tools;

15 [4] said computer network being configured with electronic
16 assessment tools to allow a health care provider to assess said
17 patient health-related data to determine progress of the patient
18 on the selected treatment program and whether information
19 relating to the selected treatment program needs to be conveyed
20 to the patient in response to said progress determination.

21
22 8. A method for monitoring health-related conditions of
23 patients, comprising:

24 [1] obtaining patient health-related data pertaining to patients
25 at a plurality of remote monitoring stations, each being
26 configured to receive respective said patient health-related data
27 from a respective said patient;

28 [2] storing accumulated health-related data pertaining to
29 health-related conditions and treatments that reveals population
30 trends and outcomes in a database of a computer network;

31 [3] receiving at said computer network said patient health-
32 related data from said remote monitoring stations pertaining to
33 respective patients;

34 [4] controlling said computer network to provide a health
35 care provider with electronic treatment establishment tools to
36 establish treatment programs for said patients based on their
37 respective patient health-related data and said accumulated
38 health-related data;

[5] controlling said computer network to revise said accumulated health-related data based on said patient health-related data;
[6] generating from said accumulated health-related data clinical data comprising outcomes of said treatment programs;
[7] receiving economic data relating to protocols used in said treatment programs;
[8] aggregating said patient health-related data, said clinical data and said economic data with said accumulated health-related data comprising population outcomes and generic standards of care; and
[9] determining from said aggregated data recommendations for improving the treatment programs.

15. A method for managing health-related conditions of patients, comprising:

[1] assigning healthcare managers to said patients, such that each said healthcare manager is assigned to a respective group of said patients;
[2] collecting healthcare data by using each said healthcare manager to collect respective patient health-related data for each respective patient in their said group of patients;
[3] determining whether each respective patient is suitable for participation in a treatment program;
[4] controlling a computer network to receive said health-related data from each of said healthcare managers, and to store said patient health-related data pertaining to each said patient in a database, said database further including accumulated data pertaining to health-related conditions and treatments that reveals population trends and outcomes;
[5] coordinating each said healthcare manager with at least one member of a primary care team to establish a treatment program for each respective patient in their said group of patients based on said patient health-related data pertaining to that respective patient and said accumulated data; and
[6] updating said accumulated data in said database based on said patient health-related data provided by said healthcare managers and identifying improvements in standards of care

1 and medical practices that can be made for different ones of the
2 health-related conditions;

3 [7] wherein the determining step comprises the steps of

4 [a] obtaining agreement from a respective patient to
5 participate in a treatment program; and

6 [b] receiving approval from a payer who will pay for
7 the treatment program;

8 [8] wherein the controlling step comprises the steps of

9 [a] receiving health-related data for a respective
10 patient comprising assessment of the patient's medical,
11 psychosocial and environmental conditions;

12 [b] receiving a plan of care initiated by the
13 corresponding one of the healthcare managers assigned to the
14 patient as a result of an interview with the patient and the
15 assessment, the plan of care being used in the establishment of
16 the treatment program for the patient.

17
18 21. A method as claimed in claim 15, wherein collecting
19 healthcare data comprises said healthcare managers developing
20 a client plan of care (CPOC) and a medical plan of care
21 (MPOC), the CPOC is developed during the interview with the
22 patient, and the MPOC is developed with at least one member
23 of the primary care team.

24
25 22. A method as claimed in claim 15, wherein the determining
26 comprises excluding a respective patient based on selected
27 criteria comprising the patient is a minor, the patient has not
28 received a selected diagnosis, and the patient cannot
29 communicate effectively, and including a respective patient
30 based on selected criteria comprising having a selected primary
31 diagnosis, and being at risk for future hospital admissions.

32 This appeal arises from the Examiner's Final Rejection, mailed
33 August 22, 2007. The Appellants filed an Appeal Brief in support of the
34 appeal on April 22, 2008. An Examiner's Answer to the Appeal Brief was
35 mailed on August 6, 2008. A Reply Brief was filed on October 6, 2008.

PRIOR ART

The Examiner relies upon the following prior art:

Russek	US 5,319,355	Jun. 7, 1994
Seare	US 5,557,514	Sep. 17, 1996
Ballantyne	US 5,867,821	Feb. 2, 1999
Summerell	US 5,937,387	Aug. 10, 1999
Joao	US 6,283,761 B1	Sep. 4, 2001
Soll	US 2003/0055679 A1	Mar. 20, 2003

REJECTIONS

Claims 1-7 stand rejected under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, and Summerell.

Claims 8-14 stand rejected under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, and Seare.

Claims 15-21 and 23-25 stand rejected under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, and Soll.

Claim 22 stands rejected under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, Soll, and Official Notice.

ISSUES

The issues pertinent to this appeal are

- Whether the Appellants have sustained their burden of showing the Examiner erred in the rejection of claims 1-7 under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, and Summerell.
 - This pertinent issue turns on whether Ballantyne and Joao fail to describe health-related data pertaining to health-related conditions and treatments that reveal population trends and

1 outcomes and the revision of data to identify improvements in
2 standards of care and medical practices.

- 3 • Whether the Appellants have sustained their burden of showing the
4 Examiner erred in the rejection of claims 8-14 under 35 U.S.C. §
5 103(a) as unpatentable over Ballantyne, Joao, and Seare.

- 6 ○ This pertinent issue turns on whether Ballantyne and Joao fail
7 to describe health-related data pertaining to health-related
8 conditions and treatments that reveal population trends and
9 outcomes and the revision of data to identify improvements in
10 standards of care and medical practices.

- 11 • Whether the Appellants have sustained their burden of showing the
12 Examiner erred in the rejection of claims 15-21 and 23-25 under 35
13 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, and
14 Soll.

- 15 ○ This pertinent issue turns on whether Ballantyne and Joao fail
16 to describe health-related data pertaining to health-related
17 conditions and treatments that reveal population trends and
18 outcomes and the revision of data to identify improvements in
19 standards of care and medical practices.

- 20 • Whether the Appellants have sustained their burden of showing the
21 Examiner erred in the rejection of claim 22 under 35 U.S.C. § 103(a)
22 as unpatentable over Ballantyne, Joao, Russek, Soll, and Official
23 Notice.

- 24 ○ This pertinent issue turns on whether the Examiner's Official
25 Notice failed to address the limitation of excluding a patient

1 from a treatment program based on criteria that the patient
2 cannot communicate effectively.

3
4 **FACTS PERTINENT TO THE ISSUES**

5 The following enumerated Findings of Fact (FF) are believed to be
6 supported by a preponderance of the evidence.

7 *Ballantyne*

8 01. Ballantyne is directed to a method and apparatus for the
9 distribution of information that is useful in any healthcare facility
10 (Ballantyne 1:13-16).

11 02. Ballantyne describes the medical information network to
12 consist of a master library, a communications interconnection
13 system, distributed processing nursing stations, individual bedside
14 patient care stations, and integrated personal data assistants
15 (Ballantyne 3:60-67 and fig. 1).

16 03. A Personal Care Station (PCS) facilitates the interaction
17 between a patient or the medical staff and the master library
18 (Ballantyne 8:66-67).

19 04. The PCS is integrated with a smart health card reader/writer
20 (Ballantyne 15:41-42). The health card contains personal data,
21 emergency data, medical history data, and present examination
22 data (Ballantyne 15:50 – 16:13). The personal data includes
23 name, address, next of kin, DOB, and insurance information
24 (Ballantyne 15:50-55). The emergency data includes data of life
25 saving importance such as blood type, allergies, medications, and
26 immediate medical history (Ballantyne 15:56-62). The medical

1 history contains information on the past medical history of the
2 patient including past diseases, injuries, operations, and associated
3 treatments (Ballantyne 15:63-67). The present examination data
4 includes information relating to the actual examination, who
5 performed the examination, where and when it was performed,
6 and the diagnosis and treatment prescribed based on the
7 examination (Ballantyne 16:6-13).

8 *Summerell*

9 05. Summerell is directed to a system and method for determining a
10 user's physiological age based on a combination of health risk and
11 health enhancing factors (Summerell 1:8-12).

12 06. Summerell describes a wellness system that collects voluntary
13 information from a user, measures the users wellness by
14 determining the user's physiological age, provides the user with
15 expert knowledge on how to improve the user's wellness, enables
16 the user to select from various options to improve the user's
17 wellness, and monitors the user's progress towards wellness
18 (Summerell 4:42-47).

19 07. Summerell also describes that the wellness system can be used
20 in conjunction with pre- and post- surgery (Summerell 6:1-13).
21 Surgeons and anesthesiologists can describe to a user the effects
22 of smoking on a patient undergoing arterial reconstruction
23 (Summerell 6:1-13). The health care facility can use the wellness
24 system to monitor the patients progress (Summerell 6:1-13).

25 *Joao*

- 1 08. Joao is directed to an apparatus and method for providing and
2 processing healthcare-related information (Joao 1:16-21).
- 3 09. Joao maintains information related to the success and failures of
4 treatment plans (Joao 17:40-41).
- 5 10. Joao describes an apparatus and method that can be utilized for
6 determining and/or ascertaining a medical diagnosis, verifying
7 and/or checking a diagnosis or treatment, or performing a self-
8 diagnosis (Joao 4:33-39). Joao further describes the evaluation
9 and verification of diagnoses, treatments, and any other part of
10 providing healthcare services (Joao 9:57-10:2). The verification
11 of a diagnosis requires determining the correctness of that
12 diagnosis (Joao 24:2-8 and 25:5-9).
- 13 11. Joao describes that a provider will access the central processing
14 computer and input patient information (Joao 25:11-14). The
15 central processing computer determines whether any medical
16 history for the patient exists and retrieves or requests a medical
17 history for the patient based on that determination (Joao 25:13-
18 19).
- 19 12. Then the patient's symptoms and examination findings are
20 obtained from the patient and transmitted to the central processing
21 computer (Joao 25:25-30). The central processing computer then
22 processes the patient's symptoms and examination findings in
23 conjunction with the patient's medical history (Joao 25:30-35).
- 24 13. After processing this information, the central processing
25 computer will perform a comprehensive diagnostic evaluation of
26 the patient (Joao 25:35-38). The central processing computer will

1 output this evaluation into a diagnostic report (Joao 25:40-42).

2 The report includes a single diagnosis or a list of possible
3 diagnoses, the respective probabilities of occurrence, and the
4 corresponding statistical information (Joao 25:43-46). The
5 diagnosis may include medical information, textbook materials,
6 laboratory materials, reference materials, video clips, hyperlinks
7 to informational sources, and other relevant information (Joao
8 26:11-19).

9 14. The central processing computer will further generate a
10 treatment report that considers possible drug interactions and/or
11 treatment interactions (Joao 25:49-53).

12 15. The central computer then transmits the diagnostic report and
13 treatment report to a medical doctor and the medical doctor can
14 choose a final diagnosis for the patient (Joao 25:54-62). The
15 doctor transmits the final diagnosis and/or treatment plan to the
16 central processing computer (Joao 25:63-66). The central
17 processing computer updates the patient's medical record based
18 on the reports (Joao 25:66-67).

19 16. The system can further be utilized to perform treatment
20 evaluations and monitor treatment plans (Joao 27:58-67). The
21 system can be accessed by providers, payers, patients, users, or
22 intermediaries in order to evaluate treatments (Joao 27:58-67).
23 The central processing computer generates an evaluation report
24 and transmits this report to a payer for the services in order to
25 assist the payer in determining whether to submit payment for the
26 services (Joao 28:38-60).

1 17. Joao further describes that providers can access the central
2 processing computer to find specific services (Joao 30:60-67).
3 The system will respond to a request from the provider and
4 identify a medical specialist that can perform the requested
5 medical services (Joao 30:60-67). The provider can additionally
6 request the central processing computer to identify a facility (Joao
7 31:5-6), a payer (Joao 31:10-11), supplies (Joao 31:26-27), and
8 other services or items required for the care of a patient.

9 18. Joao maintains a database that stores statistical data on
10 information regarding diagnoses, alternate diagnoses, treatment
11 success, treatment failure, misdiagnoses, and the success and
12 failure of experimental treatments (Joao 20:13-19). Joao further
13 uses this statistical information in the generation of a diagnostic
14 report that enables a physician to make a final diagnosis
15 determination (Joao 25:41-47). All of the data in the database can
16 be updated by any party so as to provide and ensure that the data
17 is up-to-date (Joao 25:34-39).

18 *Seare*

19 19. Seare is directed to methods and systems for analyzing medical
20 claim histories and billing patterns to statistically establish
21 treatment utilization patterns (Seare 1:21-24).

22 20. Seare describes a system that creates a profile for end users that
23 uses historical medical provider billing information (Seare 21:10-
24 12). The preferred embodiment includes a minimum of two years
25 of billing information and fifty million claims in order to develop

1 a profile (Seare 21:16-19). The system isolates and extrapolates
2 relevant billing information (Seare 22:27-32).

3 21. After collecting this data, an episode of care (EOC) is
4 determined for each diagnosis (Seare 23:6-8). An episode of care
5 is defined as all of the healthcare services provided to a patient for
6 the diagnosis, treatment, and aftercare for a specific medical
7 condition (Seare 23:7-11).

8 22. All of the information analyzed and stored in the database can
9 be presented to users in the form of reports (Seare 28:10-11).

10 *Soll*

11 23. Soll is directed to a system for disease management that
12 enhances the quality and cost-effectiveness of healthcare (Soll ¶
13 1).

14 24. Soll describes a system that interviews a patient to collect,
15 store, and analyze the patient's health information (Soll ¶ 51).
16 The information is reported to a physician to assist the physician
17 assessing the patient and in diagnostic decision making (Soll ¶
18 51). Upon completion of the physician assessment, the physician
19 inputs a patient management plan that includes educational
20 materials regarding the selected treatments (Soll ¶'s 51 and 163-
21 180).

22 *Russek*

23 25. Russek is directed to a communications and alarm system for
24 providing secure and reliable patient monitoring (Russek 1:10-12).

26. Russek describes that the scheduling information in the system includes a list of the hospital staff that are assigned to specific patients (Russek 9:28-32).

Facts Related To The Level Of Skill In The Art

27. Neither the Examiner nor the Appellants has addressed the level of ordinary skill in the pertinent art of healthcare treatment, diagnoses, and management systems. We will therefore consider the cited prior art as representative of the level of ordinary skill in the art. *See Okajima v. Bourdeau*, 261 F.3d 1350, 1355 (Fed. Cir. 2001) (“[T]he absence of specific findings on the level of skill in the art does not give rise to reversible error ‘where the prior art itself reflects an appropriate level and a need for testimony is not shown’”) (quoting *Litton Indus. Prods., Inc. v. Solid State Sys. Corp.*, 755 F.2d 158, 163 (Fed. Cir. 1985)).

Facts Related To Secondary Considerations

28. There is no evidence on record of secondary considerations of non-obviousness for our consideration.

PRINCIPLES OF LAW

Obviousness

A claimed invention is unpatentable if the differences between it and the prior art are “such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art.” 35 U.S.C. § 103(a) (2000); *KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 406 (2007); *Graham v. John Deere Co.*, 383 U.S. 1, 13-14 (1966).

1 In *Graham*, the Court held that the obviousness analysis is bottomed
2 on several basic factual inquiries: “[(1)] the scope and content of the prior art
3 are to be determined; [(2)] differences between the prior art and the claims at
4 issue are to be ascertained; and [(3)] the level of ordinary skill in the
5 pertinent art resolved.” 383 U.S. at 17. *See also KSR*, 550 U.S. at 406.

6 “The combination of familiar elements according to known methods is likely
7 to be obvious when it does no more than yield predictable results.” *Id.* at
8 416.

9 “When a work is available in one field of endeavor, design incentives
10 and other market forces can prompt variations of it, either in the same field
11 or a different one. If a person of ordinary skill can implement a predictable
12 variation, § 103 likely bars its patentability.” *Id.* at 417.

13 “For the same reason, if a technique has been used to improve one
14 device, and a person of ordinary skill in the art would recognize that it would
15 improve similar devices in the same way, using the technique is obvious
16 unless its actual application is beyond his or her skill.” *Id.*

17 “Under the correct analysis, any need or problem known in the field
18 of endeavor at the time of invention and addressed by the patent can provide
19 a reason for combining the elements in the manner claimed.” *Id.* at 420.

20
21 ANALYSIS

22 *Claims 1-7 rejected under 35 U.S.C. § 103(a) as unpatentable over*
23 *Ballantyne, Joao, and Summerell*

24 The Appellants argue these claims as a group.

25 Accordingly, we select claim 1 as representative of the group.

26 37 C.F.R. § 41.37(c)(1)(vii) (2008).

1 The Examiner found that Ballantyne describes limitations [1] and [2]
2 of claim 1, but fails to describe limitations [3] and [4] (Ans. 3-4). The
3 Examiner found that Summerell describes limitation [3] and Joao describes
4 limitation [4] (Ans. 5). The Examiner further found that a person of
5 ordinary skill in the art would have recognized the benefits of facilitating
6 healthcare services by providing access to information in order to determine
7 the progress of a patient and by providing self-monitoring equipment as
8 described by Summerell and Joao (Ans. 5-6). The Examiner found that a
9 person with ordinary skill in the art would have found it obvious to combine
10 Ballantyne, Joao, and Summerell (Ans. 5-6).

11 The Appellants contend that (1) Ballantyne fails to describe health-
12 related data pertaining to health-related conditions and treatments that reveal
13 population trends and outcomes and the revision of data to identify
14 improvements in standards of care and medical practices (Br. 8-9 and Reply
15 Br. 6-7), (2) Summerell fails to describe limitation [3] of claim 1 (Br. 10 and
16 Reply Br. 10-12), and (3) Joao fails to describe determining whether
17 information relating to a selected treatment program needs to be conveyed to
18 the patient in response to progress determination as required by limitation
19 [4] of claim 1 (Reply Br. 12-13).

20 The Appellants first contend that (1) Ballantyne fails to describe
21 health-related data pertaining to health-related conditions and treatments that
22 reveal population trends and outcomes and the revision of data to identify
23 improvements in standards of care and medical practices (Br. 8-9 and Reply
24 Br. 6-7). Ballantyne describes a system for distributing and managing
25 health-related information between the patient and healthcare service
26 providers (FF 03) but fails to specifically describe data pertaining to health-

1 related conditions and treatments that reveal population trends and outcomes
2 as required by limitation [2] of claim 1.

3 The Examiner found that the limitation directed to revealing
4 population trends and outcomes is merely an intended use (Ans. 24);
5 however, this limitation should be given patentable weight as it further limits
6 the scope of the data. The Examiner further found that the limitation for
7 identifying improvements also should not be given patentable weight
8 because it is a mere intended use of the claimed invention (Ans. 24);
9 however, the identifying of improvements should be given patentable weight
10 because it is a functional step that further limits the scope of the invention.
11 As such, the Appellants' arguments that the one reference, Ballantyne, fails
12 to describe these limitations have validity.

13 However, the Appellants overlook the fact that another reference,
14 Joao, describes health-related data pertaining to health-related conditions
15 and treatments that reveal population trends and outcomes and the revision
16 of data to identify improvements in standards of care and medical practices.
17 Joao describes storing health-related data and statistical information
18 regarding diagnoses and treatment outcomes in a database (FF 11 and FF
19 18). The statistical information is further applied towards patient health-
20 related data in order to more accurately determine a diagnosis and treatment
21 plan (FF 18). Statistical information reflects trends in the diagnoses and
22 treatments of several patients. Joao further describes that all of the health-
23 related data stored in the database can be updated such that all of the data is
24 up-to-date and comprehensive (FF 18).

25 The updating of the health-related information will also update the
26 statistical information on diagnoses and treatments and thereby will also

1 identify improvements in diagnoses and treatments by applying up-to-date
2 statistics. A person with ordinary skill in the art would have recognized the
3 benefit of using a statistical analysis of patient health-related data in the
4 diagnoses and treatment of patients and updating the statistics used in order
5 to improve the resulting diagnoses and treatments generated. As such, Joao
6 describes these features and a person with ordinary skill in the art would
7 have been motivated to combine these features described by Joao with
8 Ballantyne in order to increase the accuracy of the diagnoses and treatments
9 generated.

10 The Appellants next contend that (2) Summerell fails to describe
11 limitation [3] (Br. 10 and Reply Br. 10-12). The Appellants specifically
12 contend that Summerell does not describe that a healthcare provider creates
13 the profile for the patient and a healthcare provider does not select a
14 treatment plan as required by the antecedent basis found in limitation [2]
15 (Br. 10-12 and Reply Br. 11-12).

16 We disagree with the Appellants. Limitation [3] requires receiving
17 health-related information from a patient to be integrated into to a selected
18 treatment plan (as recited by limitation [2]), where the information is
19 obtained by asking the patient questions and using the responses given by
20 the patient.

21 Summerell describes a wellness system that presents a patient with a
22 set of questions and develops a physiological age for that patient based on
23 the information provided by the patient (FF 06). Summerell further
24 describes that a surgeon or anesthesiologist can selected a treatment program
25 to present to the patient in order to encourage and motivate the user to
26 progress pre- or post- surgery (FF 07). For example, a surgeon can present a

1 patient, who is undergoing arterial reconstruction, the effects of smoking on
2 their physiological age (FF 07). Thus, the surgeon is selecting a treatment
3 program on the wellness system for the patient. As per the Appellants'
4 contention that the healthcare provider does not create the profile for the
5 patient, there is nothing required in limitation [3] that requires a healthcare
6 provider to create a treatment program by submitting the patient information
7 as argued. As such, Summerell describes limitation [3].

8 The Appellants further contend that (3) Joao fails to describe
9 determining whether information relating to a selected treatment program
10 needs to be conveyed to the patient in response to progress determination as
11 required by limitation [4] (Reply Br. 12-13). We disagree with the
12 Appellants. Joao describes monitoring and evaluating the progress of a
13 treatment (FF 16). Joao further describes that an evaluation report, which
14 contains information regarding the progress and evaluation of a treatment, is
15 transmitted to a payer (FF 16). This can be done in response to requesting
16 payment for services rendered (FF 16). The payer for healthcare services
17 can also be the patient receiving the healthcare services. Under the broadest
18 reasonable interpretation, the payer/patient is being notified of the progress
19 of treatment. As such, Joao does describe determining whether information
20 regarding a treatment needs to be conveyed to a patient in response to a
21 progress or evaluation determination as required by limitation [4].

22 The Appellants have not sustained their burden of showing that the
23 Examiner erred in rejecting claims 1-7 under 35 U.S.C. § 103(a) as
24 unpatentable over Ballantyne, Joao, and Summerell.

25 *Claims 8-14 rejected under 35 U.S.C. § 103(a) as unpatentable over*
26 *Ballantyne, Joao, and Seare*

1 The Appellants argue these claims as a group.

2 Accordingly, we select claim 8 as representative of the group.

3 The Examiner found that Ballantyne describes all of the limitations of
4 claim 8 as discussed in the rejection of claim 1, except for limitations [6],
5 [7], [8], and [9] (Ans. 10). The Examiner found that Joao describes
6 limitation [6] and Seare describes limitations [7], [8], and [9] (Ans. 11). The
7 Examiner further found that a person of ordinary skill in the art would have
8 recognized the benefits of facilitating healthcare services by providing
9 access to information in order to accurately determine the progress of a
10 patient and by providing additional economic and health-related data to
11 make determinations described by Seare and Joao (Ans. 11). The Examiner
12 thus found that a person with ordinary skill in the art would have found it
13 obvious to combine Ballantyne, Joao, and Seare (Ans. 11).

14 The Appellants contend that (1) Ballantyne, Joao, and Seare fail to
15 describe health-related data pertaining to health-related conditions and
16 treatments that reveal population trends and outcomes and revising said data
17 based on patient health-related data and determining recommendations for
18 improving treatment programs, as argued *supra* with respect to claim 1 (Br.
19 11), (2) Seare fails to describe receiving economic data relating to protocols
20 used in these treatment programs as required by limitation [7] (Br. 12), and
21 (3) Seare and Joao fail to describe clinical data comprising outcomes of the
22 treatment programs (Br. 12).

23 The Appellants first contend that (1) Ballantyne, Joao, and Seare fail
24 to describe health-related data pertaining to health-related conditions and
25 treatments that reveal population trends and outcomes and revising said data
26 based on patient health-related data and determining recommendations for

1 improving treatment programs, as argued *supra* with respect to claim 1 (Br.
2 11). We find that Joao describes these limitations as discussed *supra* and
3 denominate a new ground of rejection within the meaning of
4 37 C.F.R. § 41.50(b) for the same reasons discussed *supra*.

5 The Appellants also contend that (2) Seare fails to describe receiving
6 economic data relating to protocols used in these treatment programs (Br.
7 12). We disagree with the Appellants. Limitation [7] requires receiving
8 economic data associated with procedures in a treatment program. Seare
9 describes compiling billing data received from various sources for each
10 specific diagnosis (FF 20 and FF 21). That is, Seare is describing the cost
11 information for each procedure used in the treatment of diagnoses. As such,
12 Seare describes receiving economic data relating to protocols used in said
13 treatment programs as required by limitation [7] of claim 8.

14 The Appellants further contend that (3) Seare and Joao fail to describe
15 clinical data comprising outcomes of the treatment programs (Br. 12). We
16 disagree with the Appellants. As discussed *supra*, Joao describes
17 maintaining data that relates to the outcomes of treatment plans, including
18 both the successes and failures of treatment programs (FF 09 and FF 10).
19 Since limitation [6] defines clinical data to comprise the outcomes of
20 treatment programs and Joao explicitly describes the storing the outcomes of
21 treatment plans, Joao therefore describes this clinical data. The Appellants
22 further contend that Seare fails to describe this limitation, however, the
23 Examiner has only relied on Joao to describe this feature. As such, this
24 contention presented by the Appellants does not persuade us of error on the
25 part of the Examiner because the Appellants are responding to the rejection
26 by attacking the references separately, even though the rejection is based on

1 the combined teachings of the references. Nonobviousness cannot be
2 established by attacking the references individually when the rejection is
3 predicated upon a combination of prior art disclosures. *See In re Merck &*
4 *Co., Inc.*, 800 F.2d 1091, 1097 (Fed. Cir. 1986).

5 The Appellants have not sustained their burden of showing that the
6 Examiner erred in rejecting claims 8-14 under 35 U.S.C. § 103(a) as
7 unpatentable over Ballantyne, Joao, and Seare.

8
9 *Claims 15-21 and 23-25 rejected under 35 U.S.C. § 103(a) as*
10 *unpatentable over Ballantyne, Joao, Russek, and Soll*

11 The Appellants argue these claims as a group.

12 Accordingly, we select claim 15 as representative of the group.

13 The Examiner found that Ballantyne describes limitations [1], [2], and
14 [3] of claim 15 as discussed *supra* in the rejection of claim 1, but fails to
15 describe limitations [4], [5], [6], [7], and [8] of claim 15 (Ans. 13-14). The
16 Examiner found that Russek describes limitation [4], Joao describes
17 limitations [5], [7b], and [8a], and Soll describes limitations [6], [7a], and
18 [8b] (Ans. 14-15). The Examiner further found that a person with ordinary
19 skill in the art would have recognized the benefits of facilitating healthcare
20 services, providing efficient and reliable communications, and providing a
21 system and method of healthcare by assigning resources to patients to
22 develop treatment plans based on health-related data as described by Joao,
23 Russek, and Soll (Ans. 15). The Examiner also found that a person with
24 ordinary skill in the art would have found it obvious to combine Ballantyne,
25 Joao, Russek, and Soll (Ans. 15).

1 The Appellants contend that (1) Ballantyne fails to describe
2 accumulated health-related data and Ballantyne and Joao fail to describe
3 updating accumulated health-related data based on patient health-related
4 data or identifying improvements in standards of care as argued *supra* for
5 claims 1 and 8 (Br. 13-15), (2) Soll fails to describe determining if a patient
6 is suitable for participation in a treatment program as required by limitation
7 [3] of claim 15 (Br. 14 and Reply Br. 18), (3) Joao fails to describe
8 developing a client plan of care (CPOC) and a medical plan of care (MPOC)
9 as required by claims 21 and 23 (Br. 14 and Reply Br. 19-20), and (4)
10 Russek fails to describe coordinating each said healthcare manager with at
11 least one member of a primary care team as required by limitation [5] of
12 claim 15 (Reply Br. 18-19).

13 The Appellants first contend that (1) Ballantyne fails to describe
14 accumulated health-related data and Ballantyne and Joao fail to describe
15 updating accumulated health-related data based on patient health-related
16 data or identifying improvements in standards of care as argued *supra* for
17 claims 1 and 8 (Br. 13-15). We find that Joao describes these limitations as
18 discussed *supra* and denominate a new ground of rejection within the
19 meaning of 37 C.F.R. § 41.50(b) for the same reasons discussed *supra*.

20 The Appellants next contend (2) Soll fails to describe determining if a
21 patient is suitable for participation in a treatment program (Br. 14). We
22 disagree with the Appellants. Limitation [3] only requires determining
23 whether a patient is suitable for a specific treatment plan. Soll describes
24 collecting patient health information in order to assist a physician in
25 determining an appropriate treatment (FF 24). Although the portion of Soll
26 cited by the Examiner (Soll ¶ 58) does describe exit interviews subsequent to

1 the administration of a treatment program, Soll also describes assessing
2 patient health information and enabling a physician to determine whether a
3 treatment plan for the patient is appropriate (FF 24). The Appellants
4 additionally contend that Soll fails to describe limitation [7][b], however, the
5 Examiner has only relied on Joao to describe this feature. As such, this
6 contention presented by the Appellants does not persuade us of error on the
7 part of the Examiner because the Appellants are responding to the rejection
8 by attacking the references separately, even though the rejection is based on
9 the combined teachings of the references. *Id.*

10 The Appellants further contend that (3) Joao fails to describe
11 developing a client plan of care (CPOC) and a medical plan of care (MPOC)
12 as required by claims 21 and 23 (Br. 14 and Reply Br. 19-20). We disagree
13 with the Appellants. Joao describes that a provider can use the central
14 processing computer to identify a medical specialist to perform a medical
15 service (FF 17). Thus, the provider is distinct from the medical specialist, or
16 primary care team. The medical specialist diagnoses the patient and
17 develops a treatment plan (FF 13). As such, the provider (or manager) is
18 working with the medical specialist (or primary care team) to develop a
19 treatment or medical care plan for the patient. Joao further describes that the
20 provider, using the central processing computer, can identify and locate all
21 other needs that a patient may have (FF 17). That is, the provider can
22 systematically manage the needs of the patient, in addition to determining
23 the medical care plan. The management of the patient's needs is a client
24 care plan because it addresses all of the needs of the patient, including the
25 medical care plan. As such, Joao does describe developing a client plan of
26 care and a medical plan of care as required by claims 21 and 23.

1 The Appellants additionally contend that (4) Russek fails to describe
2 assigning healthcare managers to said healthcare patients, such that each said
3 healthcare manager is assigned to a respective group of patients as required
4 by limitation [1] (Reply Br. 18-19). We disagree with the Appellants.
5 Limitation [1] requires the assignment of a manager to a group of patients.
6 Russek describes that scheduling information includes information regarding
7 which hospital staff is assigned to specific patients (FF 26). The hospital
8 staff includes personnel that are part of the hospital administrative staff, such
9 as managers, and personnel that are part of the medical staff, such as nurses
10 and doctors. As such, the association of staff to specific patients can include
11 managers and therefore Russek does describe limitation [1].

12 The Appellants have not sustained their burden of showing that the
13 Examiner erred in rejecting claims 15-21 and 23-25 under
14 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, and Soll.

15
16 *Claim 22 rejected under 35 U.S.C. § 103(a) as unpatentable over*
17 *Ballantyne, Joao, Russek, Soll and Official Notice*

18 The Examiner found that Ballantyne, Joao, Russek, and Soll describe
19 all of the limitations of claim 15, but fail to describe the additional
20 limitations of claim 22 (Ans. 22). The Examiner found that the steps of
21 including and excluding patients for various criteria, as required by claim 22,
22 were old and well-known in the art at the time of the invention and as such
23 the Examiner took Official Notice of these limitations (Ans. 22).

24 The Appellants contend that claim 22 recites excluding a patient from
25 a treatment program based on criteria that the patient cannot communicate

1 effectively and the Examiner's Official Notice failed to address this
2 limitation (Br. 15 and Reply Br. 20-21).

3 We disagree with the Appellants. The Examiner found that the steps
4 of including patients for various criteria were old and well-known in the art
5 (Ans. 22). The Examiner specifically found that the including and excluding
6 based on various criteria *such those claimed* are old and well-known (Ans.
7 22). As such, the Examiner's taking of Official Notice does cover excluding
8 a patient from a treatment program based on the criteria that the patient
9 cannot communicate effectively.

10 Because claim 22 depends from claim 15 and claim 15 is rejected
11 under a new ground of rejection, the rejection of claim 22 is also
12 denominated as a new ground of rejection.

13 The Appellants have not sustained their burden of showing that the
14 Examiner erred in rejecting claim 22 under 35 U.S.C. § 103(a) as
15 unpatentable over Ballantyne, Joao, Russek, Soll, and Official Notice.

17 CONCLUSIONS OF LAW

18 The Appellants have not sustained their burden of showing that the
19 Examiner erred in rejecting claims 1-7 under 35 U.S.C. § 103(a) as
20 unpatentable over Ballantyne, Joao, and Summerell.

21 The Appellants have not sustained their burden of showing that the
22 Examiner erred in rejecting claims 8-14 under 35 U.S.C. § 103(a) as
23 unpatentable over Ballantyne, Joao, and Seare.

24 The Appellants have not sustained their burden of showing that the
25 Examiner erred in rejecting claims 15-21 and 23-25 under
26 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, and Soll.

The Appellants have not sustained their burden of showing that the Examiner erred in rejecting claim 22 under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, Sol, and Official Notice.

New Ground Designation

Because we are applying the art in each of the independent claims in a manner different from that of the Examiner, with Joao describing the health-related data pertaining to health-related conditions and treatments that reveal population trends and outcomes and the revision of data to identify improvements in standards of care and medical practices, we denominate the above rejections as new grounds of rejection within the meaning of 37 C.F.R. § 41.50(b).

DECISION

To summarize, our decision is as follows:

- The rejection of claims 1-7 under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, and Summerell is sustained.
- The rejection of claims 8-14 under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, and Seare is sustained.
- The rejection of claims 15-21 and 23-25 under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, and Soll is sustained.
- The rejection of claim 22 under 35 U.S.C. § 103(a) as unpatentable over Ballantyne, Joao, Russek, Soll, and Official Notice is sustained.
- The above rejections are denominated as new grounds of rejection within the meaning of 37 C.F.R. § 41.50(b).

This Decision contains a new rejection within the meaning of 37 C.F.R. § 41.50(b) (2008).

Our decision is not a final agency action.

37 C.F.R. § 41.50(b) provides that the Appellant, WITHIN TWO MONTHS FROM THE DATE OF THE DECISION, must exercise one of the following two options with respect to the new rejection:

(1) *Reopen prosecution*. Submit an appropriate amendment of the claims so rejected or new evidence relating to the claims so rejected, or both, and have the matter reconsidered by the Examiner, in which event the proceeding will be remanded to the Examiner. . . .

(2) *Request rehearing*. Request that the proceeding be reheard under § 41.52 by the Board upon the same record. . . .

No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a). *See* 37 C.F.R. § 1.136(a)(1)(iv) (2008).

AFFIRMED; 37 C.F.R. 41.50(b)

hh

David W. Hight, VP & Chief IP Counsel
Becton, Dickinson and Company
1 Becton Drive
MC 110
Franklin Lakes, NJ 07417-1880